Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746702 | 1.00 | MTNR1A (0.41) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1746705 | 1.00 | MTNR1A (0.41) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1245267 | 0.92 | TPMT (0.41) | TPMTPDPK1CA1CA2 | |
| SCHEMBL4630812 | 0.87 | MTNR1A (0.48) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1744469 | 0.82 | ALDH1A1 (0.36) | TPMTTBXAS1CA1CA2 | |
| SCHEMBL1744472 | 0.82 | ALDH1A1 (0.36) | TPMTTBXAS1CA1CA2 | |
| SCHEMBL1744470 | 0.82 | ALDH1A1 (0.36) | TPMTTBXAS1CA1CA2 | |
| SCHEMBL1745145 | 0.82 | BCL2L1 (0.47) | TPMT | |
| SCHEMBL1745144 | 0.82 | BCL2L1 (0.47) | TPMT | |
| SCHEMBL6419987 | 0.82 | RAB9A (0.44) | MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2020-07-09 | — | — | US | disclosed |
| US-10471066-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180071304-A1 | Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists | HIGH POINT PHARMACEUTICALS, LLC | 2018-03-15 | — | — | US | disclosed |
| US-9855274-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170216303-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2017-08-03 | — | — | US | disclosed |
| US-9663481-B2 | Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists | VTV THERAPEUTICS LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140024645-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8551993-B2 | Phenoxy acetic acids as PPAR delta activators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130102610-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-8362016-B2 | Phenyl propionic acids as PPAR delta activators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2386540-A1 | Novel compounds, their preparation and use | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-7943613-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | VTVX HOLDINGS II LLC | 2009-04-09 | — | — | US | disclosed |
| EP-1979311-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471066-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | MTNR1A 164/4885MTNR1B 236/4885CHRNB2 314/4885 |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | MTNR1A 181/4885MTNR1B 100/4885CHRNB2 1112/4885 |
| US-20170216303-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | MTNR1A 233/4885MTNR1B 227/4885CHRNB2 374/4885 |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | MTNR1A 164/4885MTNR1B 236/4885CHRNB2 314/4885 |
| US-20180071304-A1 | Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists | PPARG, PPARA, PPARD | MTNR1A 164/4885MTNR1B 236/4885CHRNB2 314/4885 |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | MTNR1A 214/4885MTNR1B 233/4885CHRNB2 361/4885 |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | MTNR1A 164/4885MTNR1B 236/4885CHRNB2 314/4885 |
| US-20130102610-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | MTNR1A 214/4885MTNR1B 233/4885CHRNB2 361/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | MTNR1A 164/4885MTNR1B 236/4885CHRNB2 314/4885 |
| US-20140024645-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | MTNR1A 233/4885MTNR1B 227/4885CHRNB2 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.